Change in kidney volume growth rate and renal outcomes of tolvaptan treatment in autosomal dominant polycystic kidney disease: post-hoc analysis of TEMPO 3:4 trial. [PDF]
Higashihara E, Matsukawa M, Jiang H.
europepmc +1 more source
Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database. [PDF]
Cao P, Wang Q, Wang Y, Qiao Q, Yan L.
europepmc +1 more source
Spot Versus 24-Hour Urine Osmolality Measurement in Autosomal Dominant Polycystic Kidney Disease: A Diagnostic Test Study. [PDF]
Akbari A+9 more
europepmc +1 more source
Small cell carcinoma of the cervix with syndrome of inappropriate antidiuretic hormone secretion following chemotherapy: A case report and literature review. [PDF]
Lauzon I+4 more
europepmc +1 more source
Comparative efficacy of different drugs in acute heart failure with renal dysfunction: a systematic review and network meta-analysis. [PDF]
Lv Q+8 more
europepmc +1 more source
Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era. [PDF]
Lapão T+4 more
europepmc +1 more source
GANAB-Associated Severe Autosomal Dominant Polycystic Kidney Disease in an 18-Year-Old Female: A Case Report. [PDF]
Agrawal G+3 more
europepmc +1 more source
Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances. [PDF]
Borghol AH+5 more
europepmc +1 more source
Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients [PDF]
Gheorghiade, Mihai+4 more
core +1 more source
Efficacy of Tolvaptan in Older Adults Undergoing Cardiac Surgery: A Single-Center Retrospective Analysis. [PDF]
Chen L, Zhou M, Lv D, Qiu S.
europepmc +1 more source